Standard-dose statin therapy provides incremental clinical benefits in normocholesterolemic diabetic patients

Circulation Journal

Volumn 74, Issue 4, 2010, Pages 779-785

  Kojima, Sunao ^a   Sakamoto, Tomohiro ^b   Ogawa, Hisao ^a   Kitagawa, Akira ^c   Matsui, Kunihiko ^d   Shimomura, Hideki ^e   Kimura, Kazuo ^f   Ogata, Yasuhiro ^g   Sakaino, Naritsugu ^h  

^a KUMAMOTO UNIVERSITY   (Japan)

^b SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^c INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^d KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^e Fukuoka Tokushukai Hospital   (Japan)

^f YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^g JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

^h Amakusa Medical Center   (Japan)

Author keywords

Cholesterol; Diabetes mellitus; Statins; Type 2 diabetes mellitus

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; JAPAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLEIOTROPY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SURVIVAL TIME; UNSTABLE ANGINA PECTORIS;

AGED; CHOLESTEROL, LDL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 77950671314     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0243     Document Type: Article

References (27)

1. Jensen LO, Thayssen P, Mintz GS, Maeng M, Junker A, Galloe A, et al. Intravascular ultrasound assessment of remodelling and reference segment plaque burden in type-2 diabetic patients. Eur Heart J 2007; 28: 1759-1764.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
3. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001; 322: 15-18.
4. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
5. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
6. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulindependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
8. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005; 366: 1279-1289.
9. Standards of medical care in diabetes. Diabetes Care 2004; 27(Suppl 1): S15-S35.
10. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: Insights from mechanistic studies. Lancet 2008; 371: 1800-1809.
11. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebocontrolled trial. Lancet 2004; 364: 685-696.
12. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 2006; 368: 1155-1163.
13. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, et al. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 2006; 97: 1165-1171.
14. Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit: A two year experience with 250 patients. Am J Cardiol 1967; 20: 457-464.
15. Matsuzawa Y. Treatment by Changing the Life-style: Japan Atherosclerosis Society Guidelines for diagnosis and treatment of atherosclerotic cardiovascular diseases. Tokyo: Japan Atherosclerosis Society, 2002; 24-26.
16. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29(Suppl 1): S43-S48.
17. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559
18. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
19. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823-828
20. Tajima N, Kurata H, Nakaya N, Mizuno K, Ohashi Y, Kushiro T, et al. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: Diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Atherosclerosis 2008; 199: 455-462.
21. Nicholls SJ, Tuzcu EM, Crowe T, Sipahi I, Schoenhagen P, Kapadia S, et al. Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol 2006; 47: 1967-1975.
22. Nasu K, Tsuchikane E, Katoh O, Fujita H, Surmely JF, Ehara M, et al. Plaque characterization by virtual histology intravascular ultrasound analysis in patients with type 2 diabetes. Heart 2008; 94: 429-433.
23. Kawasaki M, Sano K, Okubo M, Yokoyama H, Ito Y, Murata I, et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol 2005; 45: 1946-1953.
24. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239.
25. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: Molecular mechanisms and clinical results. Trends Mol Med 2008; 14: 37-44.
26. Nishino M, Hoshida S, Kato H, Egami Y, Shutta R, Yamaguchi H, et al. Preprocedural statin administration can reduce thrombotic reaction after stent implantation. Circ J 2008; 72: 232-237.
27. Huang SM, Weng KP, Chang JS, Lee WY, Huang SH, Hsieh KS. Effects of statin therapy in children complicated with coronary arterial abnormality late after Kawasaki disease: A pilot study. Circ J 2008; 72: 1583-1587.